** Shares of drug developer Amarin AMRN.O up 11% at $14.01 premarket
** Co enters into long-term license and supply agreement with Italy-based pharmaceutical firm Recordati RECI.MI to sell Vazkepa in 59 countries, including Europe
** Vazkepa is approved to treat high levels of triglycerides — blood fat that can increase risk of heart disease in the European Union
** The drug is sold under the brand name Vascepa in the United States
** As part of the deal, Amarin will get $25 million in upfront payment, and is eligible to receive up to $150 million if certain sales milestones are achieved
** As of last close, stock is up about 30% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.